New & Novel
Exhaled breath to screen for malignant pleural mesothelioma: a validation study
The European Respiratory Journal 2017 December 21 [Link] Lamote K, Vynck M, Thas O, Van Cleemput J, Nackaerts K, van Meerbeeck JP Abstract Malignant pleural mesothelioma (MPM) is predominantly caused by asbestos exposure and has a poor prognosis. Breath contains volatile organic compounds (VOCs) and can be explored as an early detection tool. Previously, we…
Read MoreEstimating past inhalation exposure to asbestos: A tool for risk attribution and disease screening
International Journal of Hygiene and Environmental Health 2017 October 7 [Epub ahead of print] [Link] Cherrie JW, McElvenny D, Blyth KG Abstract INTRODUCTION: Late presentation is common in mesothelioma. Reliable assessment of past exposure to asbestos is a necessary first step for risk attribution and for the development of a future screening programme. Such a…
Read MoreChimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM)
Cancers 2017 September [Link] Klampatsa A, Haas AR, Moon EK, Albelda SM Abstract Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes in leukemias and is now being explored in solid tumors. CARs…
Read MoreMalignant Pleural Mesothelioma: State of the art and advanced cell therapy
European Journal of Medicinal Chemistry 2017 August [Epub ahead of print] [Link] Facchetti G, Petrella F, Spaggiari L, Rimoldi I Abstract Malignant Pleural Mesothelioma (MPM) is an aggressive malignancy highly resistant to chemotherapy, with a response rate of 20% of patients and for this reason an efficient treatment is still a challenge. Platinum-based chemotherapy in…
Read MoreIntraoperative adjuncts for malignant pleural mesothelioma
Translational Lung Cancer Research 2017 June [Link] Chan WH, Sugarbaker DJ, Burt BM Abstract Malignant pleural mesothelioma (MPM) is a rapidly fatal disease. Multimodality surgically based therapies may extend survival in select patients, however, local relapse after resection is common. Novel intraoperative adjunctive therapies including heated intraoperative chemotherapy (HIOC), heated intraoperative povidone-iodine (PVP-I), and photodynamic…
Read MoreNovel systemic therapy against malignant pleural mesothelioma
Translational Lung Cancer Research 2017 June [Link] Mancuso MR, Neal JW Abstract Malignant pleural mesothelioma is an aggressive tumor of the pleura with an overall poor prognosis. Even with surgical resection, for which only a subset of patients are eligible, long term disease free survival is rare. Standard first-line systemic treatment consists of a platinum…
Read MoreCap-dependent translational control of oncolytic measles virus infection in malignant mesothelioma
Oncotarget 2017 June [Epub ahead of print] [Link] Jacobson BA, Sadiq AA, Tang S, Jay-Dixon J, Patel MR, Drees J, Sorenson BS, Russell SJ, Kratzke RA Abstract Malignant mesothelioma has a poor prognosis for which there remains an urgent need for successful treatment approaches. Infection with the Edmonston vaccine strain (MV-Edm) derivative of measles virus…
Read MoreThe inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells
Stem cell research & therapy 2017 May 25 [Link] Pattarozzi A, Carra E, Favoni RE, Würth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A Abstract BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after…
Read MoreA novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair.
Journal of Thoracic Oncology 2017 April [Epub ahead of print] [Link] Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, Felley-Bosco E Abstract INTRODUCTION: BRCA1-associated protein-1, BAP1, is a tumor suppressor involved in multiple cellular processes such as transcriptional regulation, chromatin modification by deubiquitinating histone 2A and DNA repair. BAP1 mutations are…
Read MoreMesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells
Molecular Cancer 2017 March [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28288645″>Link] He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y Abstract BACKGROUND: Lung cancer and pleural mesothelioma are two of the most deadly forms of cancer. The prognosis of lung cancer and mesothelioma is extremely poor due to limited treatment modalities and lack of understanding…
Read More